image
Journey Medical Corporation DERM
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
Watchlist
$ 6.51
2.52 %
$ 152 M
Market Cap
-17.59
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one DERM stock under the worst case scenario is HIDDEN Compared to the current market price of 6.51 USD, Journey Medical Corporation is HIDDEN

DERM Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one DERM stock under the base case scenario is HIDDEN Compared to the current market price of 6.51 USD, Journey Medical Corporation is HIDDEN

DERM Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one DERM stock under the best case scenario is HIDDEN Compared to the current market price of 6.51 USD, Journey Medical Corporation is HIDDEN

DERM Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart DERM

image
1M -24%
6M 45%
1Y 15%
3Y 74%
5Y --%
All
$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
56.1 M REVENUE
-29.11%
Growth Rates
1Year -29.11%
3Years -3.84%
5Years 9.96%
7Years 43.22%
10Years 22.63%
-13.7 M OPERATING INCOME
-559.77%
Growth Rates
1Year -559.77%
3Years 18.58%
5Years -29.20%
7Years 35.68%
10Years 8.06%
-14.7 M NET INCOME
-280.79%
Growth Rates
1Year -280.79%
3Years 30.65%
5Years -38.23%
7Years 35.12%
10Years 7.47%
-9.13 M OPERATING CASH FLOW
-174.18%
Growth Rates
1Year -174.18%
3Years -61.15%
5Years -15.01%
7Years 29.36%
10Years 11.62%
-15 M INVESTING CASH FLOW
-200.00%
Growth Rates
1Year -200.00%
3Years -14.47%
5Years -44.27%
7Years 24.21%
10Years 18.03%
17 M FINANCING CASH FLOW
453.73%
Growth Rates
1Year 453.73%
3Years -31.56%
5Years 46.66%
7Years -37.62%
10Years -20.76%
13.1 M REVENUE
-3.53%
Growth Rates
1Year -29.11%
3Years -3.84%
5Years 9.96%
7Years 43.22%
10Years 22.63%
-3.32 M OPERATING INCOME
-148.79%
Growth Rates
1Year -559.77%
3Years 18.58%
5Years -29.20%
7Years 35.68%
10Years 8.06%
-4.07 M NET INCOME
-267.78%
Growth Rates
1Year -280.79%
3Years 30.65%
5Years -38.23%
7Years 35.12%
10Years 7.47%
-2.83 M OPERATING CASH FLOW
-127.28%
Growth Rates
1Year -174.18%
3Years -61.15%
5Years -15.01%
7Years 29.36%
10Years 11.62%
0 INVESTING CASH FLOW
100.00%
Growth Rates
1Year -200.00%
3Years -14.47%
5Years -44.27%
7Years 24.21%
10Years 18.03%
3.6 M FINANCING CASH FLOW
-66.13%
Growth Rates
1Year 453.73%
3Years -31.56%
5Years 46.66%
7Years -37.62%
10Years -20.76%
Balance Sheet Journey Medical Corporation
image
Current Assets 48.2 M
Cash & Short-Term Investments 20.3 M
Receivables 10.2 M
Other Current Assets 17.6 M
Non-Current Assets 32.1 M
Long-Term Investments 0
PP&E 199 K
Other Non-Current Assets 31.9 M
25.31 %12.75 %21.99 %39.71 %Total Assets$80.2m
Current Liabilities 35.2 M
Accounts Payable 16 M
Short-Term Debt 791 K
Other Current Liabilities 18.3 M
Non-Current Liabilities 25 M
Long-Term Debt 25 M
Other Non-Current Liabilities 0
26.67 %30.47 %41.54 %Total Liabilities$60.2m
EFFICIENCY
Earnings Waterfall Journey Medical Corporation
image
Revenue 56.1 M
Cost Of Revenue 20.9 M
Gross Profit 35.3 M
Operating Expenses 48.9 M
Operating Income -13.7 M
Other Expenses 995 K
Net Income -14.7 M
60m60m50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)56m(21m)35m(49m)(14m)(995k)(15m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
62.81% GROSS MARGIN
62.81%
Averages
1Year 62.81%
3Years 62.45%
5Years 60.75%
7Years 67.26%
10Years 77.08%
-24.36% OPERATING MARGIN
-24.36%
Averages
1Year -24.36%
3Years -21.45%
5Years -17.37%
7Years -82.46%
10Years -868.48%
-26.14% NET MARGIN
-26.14%
Averages
1Year -26.14%
3Years -23.74%
5Years -25.81%
7Years -91.70%
10Years -878.86%
-73.11% ROE
-73.11%
Averages
1Year -73.11%
3Years -88.84%
5Years -63.96%
7Years 323.26%
10Years 198.19%
-18.28% ROA
-18.28%
Averages
1Year -18.28%
3Years -17.16%
5Years -17.30%
7Years -20.02%
10Years -25.81%
-29.95% ROIC
-29.95%
Averages
1Year -29.95%
3Years -34.13%
5Years -25.93%
7Years -24.34%
10Years -31.04%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Journey Medical Corporation
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -14.7 M
Depreciation & Amortization 3.42 M
Capital Expenditures 0
Stock-Based Compensation 6.1 M
Change in Working Capital -3.77 M
Others -302 K
Free Cash Flow -9.13 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Journey Medical Corporation
image
Wall Street analysts predict an average 1-year price target for DERM of $10.5 , with forecasts ranging from a low of $10.5 to a high of $10.5 .
DERM Lowest Price Target Wall Street Target
10.5 USD 61.29%
DERM Average Price Target Wall Street Target
10.5 USD 61.29%
DERM Highest Price Target Wall Street Target
10.5 USD 61.29%
Price
Max Price Target
Min Price Target
Average Price Target
1111101099887766554433Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Journey Medical Corporation
image
Sold
0-3 MONTHS
69.1 K USD 3
3-6 MONTHS
818 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
72.9 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosacea Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosacea globenewswire.com - 1 week ago
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz. globenewswire.com - 2 weeks ago
Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript Journey Medical Corporation (NASDAQ:DERM ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srinivas Sidgiddi - Vice President, Research and Development Ramsey Alloush - Chief Operating Officer and General Counsel Conference Call Participants Scott Henry - AGP Kalpit Patel - B. Riley Securities Thomas Flatten - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. seekingalpha.com - 1 month ago
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates Journey Medical Corporation (DERM) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.53 per share a year ago. zacks.com - 1 month ago
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz. globenewswire.com - 1 month ago
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET globenewswire.com - 1 month ago
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last? Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 2 months ago
Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? Journey Medical (DERM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 2 months ago
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer (“COO”). Mr. Alloush will continue to also serve as the Company's General Counsel. globenewswire.com - 2 months ago
Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript Journey Medical Corporation (NASDAQ:DERM ) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - Roth Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by. seekingalpha.com - 3 months ago
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates Journey Medical Corporation (DERM) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.12 per share a year ago. zacks.com - 3 months ago
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz. globenewswire.com - 3 months ago
8. Profile Summary

Journey Medical Corporation DERM

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 152 M
Dividend Yield 0.00%
Description Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Contact 9237 East Via de Ventura Boulevard, Scottsdale, AZ, 85258 https://journeymedicalcorp.com
IPO Date Nov. 12, 2021
Employees 41
Officers Mr. Joseph M. Benesch Chief Financial Officer & Corporate Controller Mr. Louis Donati Director of Market Access Mr. Claude Maraoui Founder, President, Chief Executive Officer & Director Jaclyn Jaffe Senior Director of Corporate Operations Mr. Ramsey Alloush Chief Operating Officer, General Counsel & Company Secretary Mr. Robert Nevin Chief Commercial Officer Dr. Lindsay Allan Rosenwald Executive Chairman